CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Another problem with gene nomenclature is when a gene has one or more aliases. One of the best examples of this, Dr. Tsuchiya says, is ERBB2. “Everyone knows it as HER2, but the approved gene symbol is ERBB2, which is not as well known. As with the KMT2A (MLL) gene symbol, there is a lot of literature out there with the alias gene symbol HER2.” It’s to avoid the confusion of this and other aspects of gene naming that she uses the HGNC website (www.genenames.org) frequently in her practice. The online database there contains all approved human gene symbols.
The gene nomenclature process is mostly a cooperative one, she explains. “The HGNC updates the names on a rolling basis. And the HGNC can’t require anyone to go through the organization to name a gene or rename a gene. They can strongly recommend it. But they are relying on journal editors, manuscript reviewers, and professional societies to enforce that recommendation because they can’t require it.”
What’s unique about the most recent gene nomenclature naming guidelines, Dr. Tsuchiya says, is that there are fewer name changes in the offing (Bruford E, et al. Nat Gen. 2020;52[8]:754–758). “Over time, the committee has come to recognize it’s a problem when there are frequent changes to gene names. It’s disconcerting when you realize all of a sudden this has happened.”
“You tend to figure that out in different ways,” she adds. For example, “Sometimes clinicians will order testing based on specific gene symbols, and there’s difficulty if they’re searching under a name that the laboratory doesn’t have that test designated as. Those are where potential patient safety issues arise,” Dr. Tsuchiya says.
Dr. Tsuchiya
Or, “You’ll be working on a case and researching a gene, and then you’ll realize the name has changed. The committee came to recognize that as technology has evolved and genetic testing has taken on more importance, there was not a good way to disseminate this information. So stabilizing the gene names and symbols should be one of their priorities, and it’s one thing the publication emphasizes. Because these names are internationally used.”
Having a name that reflects the character and function of the gene product is another priority, Dr. Tsuchiya says. As the HGNC describes its basic approach to gene symbols and names: “Ideally, gene symbols are short, memorable, and pronounceable, and most gene names are long-form descriptions of the symbol. Names should be brief and specific, and should convey something about the character or function of the gene products but not attempt to describe everything known.”
Says Dr. Tsuchiya: “There are multiple reasons why gene names have changed over the years,” and making the names meaningful is one of the reasons. “Very early on, when the HGNC was initially developed, they decided the gene names should reflect the character and function of the gene product, which is usually, though not always, a protein.”
A gene name might get the axe because it could be perceived as pejorative. The genes formerly known as DOPEY1 and DOPEY2 are examples. “It just wasn’t the greatest thing to sign out a patient report that the patient’s parents were going to potentially look at, by using the name DOPEY1 or DOPEY2.” Those were renamed to DOP1A (DOP1 leucine zipper like protein A) and DOP1B (DOP1 leucine zipper like protein B).
Another instance involved a common feature of spreadsheet software that was leading to too many errors in the way a gene name was displayed. That occurred with SEPT1 and MARCH1 symbols, which were routinely autocorrected to a date; they were changed to SEPTIN1 and MARCHF1 to avoid this autocorrection.
Sometimes the researcher who discovered a gene may have selected the name arbitrarily. “There may have been no rational basis behind what they chose,” Dr. Tsuchiya says. “So at some point there was the realization that we need rational and standardized nomenclature. That’s when the committee decided it should be primarily based on the function of the gene product. For genes within the same family of genes that have similar function, it makes sense for those to have similar names too.”
An added source of stability on the HGNC’s website is the display of each gene’s HGNC ID as well as its symbol and name, she says. “That’s very important because the HGNC ID is much more stable than the symbols or names.”
Having an invariant like the ID helps avoid problems, she says. “With a lot of current genetic testing, such as with chromosomal microarrays and NGS, they use a bioinformatics pipeline for data analysis, and if you have a gene name in your pipeline that changes, you can run into problems where the new gene name won’t be recognized by your pipeline. The HGNC ID is one way to mitigate that problem instead of using the actual gene symbol.”
Another important feature of gene nomenclature in practice is its open-access nature, Dr. Tsuchiya notes. “All of us have access to it—basically anybody who has to use gene names or symbols in their practice in the laboratory or on the receiving end, the clinicians. It’s important for all of us to be able to look up the most recent approved gene name and symbol.”
One of the ways professional societies like the CAP have tried to mitigate the problem of lack of recognition of a newly approved gene symbol is with a standardized format, she says. “You’re supposed to use the approved symbol first, then the commonly known or previous symbol in parentheses after it. It doesn’t get rid of all the problems that can occur with lack of recognition, but it can help. The same with HER2. You should really use ERBB2 and then HER2 in parentheses after it.”
The HGNC advises authors to quote the approved gene symbol (e.g. BRAF) at least once in the abstract of any publication, along with the gene’s unique HGNC ID number. The format would be HGNC:number (for example, HGNC:1097).
While it’s a top HGNC priority to stabilize gene names, there are still reasons why the names might change in the future, Dr. Tsuchiya says. One reason is that some gene symbols were never meant to be permanent because nothing was known about their function when they were discovered. “They were meant to be placeholder symbols. For example, genes that start with KIAA or that have ‘orf’ in the name in lowercase, many of those will change in the future when their function is discovered. They were never meant to be permanent names to begin with.”
“Some of them are symbols that we do use clinically not infrequently. For example there is a fusion that occurs in low-grade gliomas with one of the KIAA genes, and we’ve gotten used to using that name. It’s going to be hard to get used to if that changes.” However, she adds, the HGNC might not change some of those names for that reason. “The plan is to consider those on a case-by-case basis.”
A helpful feature of the HGNC website are “tags” that appear on the symbol report page for a gene. The tags have an icon that looks like a luggage or sales tag. One example is the “stable symbol” tag, which indicates that the gene symbol has been reviewed by HGNC, is considered stable, and should not be subject to future change.
In summary, Dr. Tsuchiya says, “There’s a problem when genes have multiple names, either because different researchers in the past gave the same gene different names, or the name is changed in the present. But it’s problematic if everyone is using something different.” As the guidelines reflect, “The HGNC has developed a standardized and rational approach to designating gene names and symbols that everyone should be using.”
Anne Paxton is a writer and attorney in Seattle.